Novel Nonlinear and RR-based Methods for Inappropriate ICD Therapy Reduction by Newell, Samuel





A THESIS  
SUBMITTED TO THE FACULTY OF THE  









IN PARTIAL FULFILLMENT OF THE REQUIREMENTS  
FOR THE DEGREE OF  











brought to you by COREView metadata, citation and similar papers at core.ac.uk





















First and foremost, I’d like to thank my advisor, Alena Talkachova, for 
challenging me over the last two and a half years. Learning how to do proper research is 
not easy, and she asked many difficult questions to develop me as a researcher. However, 
I always knew she had my best interests at heart, and I always knew I could ask her for 
support whenever I needed it. 
To everyone in the Talkachova lab, thank you for your support over the last few 
years. Your feedback on my presentations, manuscripts and other research has been vital 
in my development as a researcher. It was my pleasure to have worked with each one of 
you. 
Lastly, to my parents and family, thank you for supporting my decision to pursue 
my education further. I am fortunate that you have chosen to support me along my 
academic journey and for this I am grateful. I ask for your continued support as my 






Implantable cardioverter-defibrillators (ICD) are a commonly implanted device 
used to deliver arrythmia terminating therapy to the heart in the presence of life-
threatening arrythmias such as ventricular fibrillation and ventricular tachycardia. 
However, not all therapies, shocks or anti-tachycardia pacing (ATP), are appropriate. In 
many instances, therapy is delivered when the heart is in an abnormal, but non-life-
threatening arrythmia such as atrial fibrillation. While major medical device companies 
have devised numerous strategies to eliminate these cases of inappropriate therapy, there 
remains room for improvement. Thus, the goal of this thesis is to describe the 
development of novel strategies to discriminate between appropriate and inappropriate 
ICD therapy. The strategies use nonlinear measures and RR interval measures fed into 
principal component analysis or linear combination scores to discriminate. The final 
method using linear combination scores showed near 100% discrimination between 
appropriate and inappropriate therapy events retrospectively and 100% discrimination in 
a pseudo real time study. Thus, this strategy shows immense promise for use in a future 
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Chapter 1 – Introduction 
1.1 – ICD Statistics and Inappropriate Therapy 
Roughly 150,000 implantable cardioverter-defibrillators (ICD) are implanted in the 
United States annually [1]. These life saving devices deliver therapy to the heart in the 
form of anti-tachycardia pacing (ATP) or high energy shocks during life threatening 
cardiac arrhythmias such as ventricular fibrillation (VF) and ventricular tachycardia 
(VT). Thus, physicians world-wide often opt to implant them in patients deemed high 
risk for developing these life-threatening arrythmias. In fact, multiple studies have shown 
that ICDs decrease all-cause mortality in heart failure patients [2, 3]. 
 Despite the clear beneficial nature of ICDs, there are many drawbacks associated 
with them, mainly infection, cost and inappropriate therapy. Inappropriate therapy is any 
delivery of therapy when the heart is not in a life-threatening arrythmia such as VT/VF. 
With transvenous (TV)-ICDs it most commonly occurs due to non-life threatening 
arrythmias originating from the atria, known as supraventricular arrythmias. Among the 
most common of these, atrial fibrillation (AF) is the leading reason of inappropriate 
therapy for TV-ICD devices [4]. Given AF is an epidemic itself, affecting millions of 
Americans [5], this is not surprising. Other common reasons for inappropriate therapy for 
TV-ICDs includes and is not limited to supraventricular tachycardia (SVT) and 
oversensing due to over-sensed cardiac signals, external signals or device malfunction 
such as lead fracture. In the newest subcutaneous (S)-ICD devices oversensing is the 
primary reason for inappropriate therapy [6]. 
Inappropriate shocks had a 1 year incidence of 2.4% and 2.5% cases of therapy in 
the newest subcutaneous (S)-ICD and single lead TV-ICD devices respectively [7, 8] (see 
Figure 1). Inappropriate therapy (shocks and ATP) had a 1 year incidence of 3.4% in the 
single lead TV-ICD devices [7]. While these numbers are significant improvements over 
past statistics due to improved detection algorithms and therapy delivery strategies, they 
disguise the problem as 14% of shocks were inappropriate in the recent PainFree study 
[7]. This is of major concern because multiple studies have shown that high rates of 
inappropriate shocks lead to lower quality of life and increased morbidity and mortality 
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[9, 10]. So, while progress has been made, there still is room for improvement in 
lowering the number of inappropriate therapies. 
 
          
 
1.2 – Current Methods for Therapy 
Deciding when to deliver therapy is a difficult task as evidenced by the number of 
inappropriate therapies delivered by current devices. One wants to ensure all life-
threatening arrythmias have therapy delivered to them while minimizing the amount of 
inappropriate therapy. However, current ICDs just rely primarily upon the rate of the 
tachycardia for making the decision to deliver therapy. Medtronic and Boston Scientific 
(BSci) TV-ICDs do so by detecting if a certain percentage of RR intervals in a window 
are less than a threshold time length set by the physician. Recent clinical studies have set 
this threshold near 350 ms for VT and 320 ms for VF in their primary prevention patients 
[4, 7]. Traditional windows range from 10 to 24 RR intervals in length, but the PainFree 
Study demonstrated that windows of 40 RR intervals were effective at reducing the 
number of inappropriate therapies [7]. After an initial decision to initiate therapy is made, 
ATP is delivered, unless it has been programmed off or the tachycardia rate is below a 
programmed threshold time length. However, the TV-ICD will continue to monitor the 
percentage of RR intervals less than the threshold in the window after ATP is delivered 
and will begin charging. Unless an exit condition is met because a percentage of RR 
intervals in the window are now above the threshold, the device will shock the heart. In 
Figure 1: Recent clinical studies showing 1 year incidence of inappropriate shocks. 
Columns 1-8 adapted from Boston Scientific [8] and augmented with the last column. 
The last columns data is taken from the PainFree trial of a Medtronic device to 


























Figure 2 we see two examples of TV-ICDs making an appropriate decision to deliver 
ATP and one example of a TV-ICD making an inappropriate decision to deliver ATP as 
well as a shock. S-ICDs rely upon a slightly different strategy. When the average of the 
last 4 RR intervals is below the set VT/VF threshold the device enters into a tachycardia 
state and stays in this state unless 24 consecutive beats of at least 40 ms greater than the 
threshold occur [11]. If the device does not exit the tachycardia state within a desired 
duration, then therapy is initiated. 
 Beyond rate-based decision making, a variety of strategies have been developed 
in the last few decades to reduce the amount of inappropriate therapy. They typically look 
at either the stability, onset and morphology of the signal or utilize a variety of filters to 
lessen oversensing. Stability analysis looks at the regularity of the RR intervals because 
SVT/AF often has more irregular RR intervals than VF/VT. Onset analysis determines if 
the heart rhythm suddenly changed or gradually changed as SVT/AF often onset more 
gradually than VT/VF. Lastly, morphology analysis uses wavelets and vector analysis to 
determine if the electrocardiogram (EGM) signal looks like the patients baseline rhythm 
signal or a new rhythms signal by comparing the EGM against baseline QRS templates. 
However, all of these enhancements can be programmed off by the physician and only 
function in what’s commonly referred to as the conditional rate zone: the region below 
the VF threshold and above the VT threshold, typically 300-350 ms. Thus, they often fail 
to eliminate AF/SVT rhythms either due to the device programming, failure to recognize 
an AF/SVT in the conditional rate zone or because the rate is below the conditional rate 
zone. 














Figure 2: A (Top): A plot of RR intervals taken from the case report of a Boston 
Scientific (BSci) single chamber TV-ICD, the Dynagen EL ICD D150 device, 
demonstrating an App therapy for a rhythm classified as VT after adjudication by a 
cardiologist. The black oval demonstrates 17 RR intervals below the VF threshold of 
300 ms prior to therapy delivery in the form of ATP at the red arrow. B (Middle): RR 
interval plot taken from the case report of a Medtronic single chamber TV-ICD, the 
Evera XT VR. The rhythm identified by the cardiologist was VF in this instance and 
thus the therapy deemed App. The black oval encompasses 30 RR intervals below 
the VF threshold of 300 ms prior to ATP therapy at the red arrow. C (Bottom): 
Another plot of RR intervals taken from the case report of the same device type as 
A. However, the rhythm was classified as AF by the cardiologist and thus the 
therapy in the form of ATP is deemed Inn. The black oval shows 11 RR intervals 
below the VF threshold of 300 ms prior to ATP therapy at the red arrow. The next 







1.3 – Motivation & Research Questions 
While inappropriate therapy reduction strategies have improved in recent years, 
there is still a need to improve the therapy decision algorithms in order to reduce the 
number of inappropriate therapies, primarily inappropriate shocks. Thus, the goal of this 
thesis was to develop novel strategies for discrimination between inappropriate and 
appropriate therapy. The basis of the strategies was to use 4 novel nonlinear metrics: 
multiscale frequency, multiscale entropy, shannon entropy and kurtosis, along with 7 
standard RR based metrics: MeanRR, pnn50, RMS, STD, SD1, SD2 and SD1/SD2, fed 
into either principal component analysis or linear combination scores to discriminate 
between inappropriate and appropriate therapy. To develop the algorithm beyond this 
basis, the thesis addressed these 5 primary research questions:  
1) Because this study was retrospective, the signal window length could be 
arbitrarily chosen given enough signal was available. However, a short window will have 
a more stationary signal, while a long window may provide more information. Thus, an 
appropriate window length for discrimination needed to be determined. As such the first 
research question asked was: Does a long or short RR window prior to therapy lead to 
better retrospective discrimination? 
2) An appropriate therapy could be in response to either VF or VT while 
inappropriate therapy was almost always in response to AF in our dataset. Thus, it was 
desired to know if the novel strategies could discriminate therapy in response to VF and 
VT from therapy in response to AF or only one or the other. Manufacturer discrepancies 
in “out of the box” programming could also result in differences in the ability of the 
novel strategies to discriminate appropriate and inappropriate therapy. Thus, the second 
research question asked was: Does arrythmia type and/or manufacturer influence 
discrimination? 
3) The results of research question two demonstrated that the manufacturer 
influenced our ability to discriminate between appropriate and inappropriate therapy. 
Thus, if the dataset was split into two separate datasets, it could improve the ability of the 
strategies to discriminate between appropriate and inappropriate therapy. The third 
research then became: Does separating the data by manufacturer into two separate 
datasets improve discrimination? 
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4) In answering research questions 1-3, principal component analysis was utilized. 
However, simpler, linear combination scores i.e. summations of the 11 metrics, may also 
prove sufficient for discrimination. The advantage of the linear combination score was 
there was a small amount of supervision used to choose which parameters to sum as only 
statistically significant parameters were used in the formation of them. Thus, to prove 
that the linear combination scores, titled “therapy scores,” were equally sufficient at 
retrospectively discriminating appropriate and inappropriate therapy the fourth research 
question asked was: Do the therapy scores discriminate appropriate and inappropriate 
therapy? 
5) Research questions 1-4 addressed if the novel strategies could discriminate 
retrospectively. However, the aforementioned rate decision therapy decision algorithms 
run in real time. As such, the fifth research question became: Do the retrospective 
strategies work for real time decision making? 
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Chapter 2 - Methods 
2.1 – Data Description 
55 Cardiologist adjudicated manufacturer case reports with at least one therapy 
delivery event were provided in the form of pdf files by Dr. Selçuk Adabag in accordance 
with an institutional review board (IRB) approved protocol and stored in accordance with 
this protocol. Table 1 below contains information on all 55 of the received case reports. 
Upon receiving the case reports, the EGM signals of each case report were reviewed for 
their ability to be digitized into ASCII. 5 case reports were excluded at this point because 
they had thick solid lined grids obscuring much of the EGM signals on the pdf. 1 other 
case report was excluded because it came from a different manufacturer than all of the 
other devices and did not provide at least 20 RR intervals of EGM signal prior to therapy 
required for analysis. This left 49 acceptable case reports with a total of 54 therapy 
events. 
Table 1: Overall information of received case reports. Excluded case reports have the 














Device Type Manufacturer 
# of RR intervals 
prior to therapy 
available for 
digitization up to 
40 







2 2   no 
Single 
Chamber 
Medtronic 26 & 26 




4 4  VF no 
Dual 
Chamber 
Biotronik < 20 
5 1  VT yes 
Single 
Chamber 
Boston Sci 30 
6 1  VT yes 
Single 
Chamber 
Boston Sci 30 
7 1  VF yes Subcutaneous Boston Sci 40 
8 1  VF yes Subcutaneous Boston Sci 40 
9 1  VF yes Subcutaneous Boston Sci 40 




11 1  VT yes 
Single 
Chamber 
Boston Sci 29 
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12 1  VT yes 
Single 
Chamber 
Boston Sci 30 
13 1  VT yes 
Single 
Chamber 
Boston Sci 29 
14 1  VT yes 
Single 
Chamber 
Boston Sci 29 
15 1  VT yes 
Single 
Chamber 
Boston Sci 29 
16 1  VT yes 
Single 
Chamber 
Boston Sci 29 
17 1  VT yes 
Single 
Chamber 
Boston Sci 30 
18 2  VT yes 
Single 
Chamber 
Boston Sci 30 & 30 












22  1 AF yes 
Single 
Chamber 
Boston Sci 40 
23  2 AF yes 
Single 
Chamber 
Boston Sci 40 & 34 
24  1 AF yes 
Single 
Chamber 
Boston Sci 40 
25  1 AF yes 
Single 
Chamber 
Boston Sci 40 
26  1 AF yes 
Single 
Chamber 
Boston Sci 40 
27  2 AF yes 
Single 
Chamber 
Boston Sci 40 & 27 




























35 1  VT yes Subcutaneous Boston Sci 40 
36 1  VF yes Subcutaneous Boston Sci 40 
37 1  VF yes Subcutaneous Boston Sci 40 
38 1  VF yes Subcutaneous Boston Sci 40 
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39 1  VF yes Subcutaneous Boston Sci 40 
40 1  VF yes Subcutaneous Boston Sci 40 
41 1  VF yes Subcutaneous Boston Sci 40 
42 1  VF yes Subcutaneous Boston Sci 40 
43 1  VT yes Subcutaneous Boston Sci 40 
44 1  VF yes Subcutaneous Boston Sci 40 
45 1  VF yes Subcutaneous Boston Sci 40 
46 2  VT yes 
Single 
Chamber 
Medtronic 28 & 25 
47  2 AF yes 
Single 
Chamber 
Medtronic 40 & 21 




49 1  VT yes Subcutaneous Boston Sci 40 
50  1 NSVT yes Subcutaneous Boston Sci 40 
51 1  VT yes Subcutaneous Boston Sci 40 
52 1  VT yes 
Single 
Chamber 
Boston Sci 33 
53 1  VT yes 
Single 
Chamber 
Boston Sci 33 









All 49 acceptable case reports were from either single chamber TV-ICD or S-ICD 
devices, two of the most commonly implanted ICD types. A single chamber TV-ICD is 
an ICD with a single transvenous lead implanted directly into the right ventricle (see 
Figure 3). When therapy is delivered, it is done so through this lead. Dual chamber and 
Biventricular TV devices are less common and are only indicated when pacing of both 
the atria and ventricles is indicated. Rather than transvenous leads, the S-ICD has a single 
lead placed directly over the right ventricle just above the rib cage (see Figure 3). By 
placing the lead subcutaneous and not transvenous, the S-ICD overcomes a variety of 
issues with traditional TV-ICDs including lead fracture, cardiac perforation, etc. 
However, they still deliver inappropriate therapy at similar rates as TV-ICDs [8], but 






    
 
The 49 acceptable case reports with 54 total therapy events had their far-field or 
“Shock” EGM digitized for up to 40 RR intervals prior to delivery of therapy for each 
event with at least 20 RR intervals of non-paced or shocked EGM on the case report. All 
case reports from S-ICD devices had at least 40 RR intervals of EGM prior to the 
therapy, but a majority of the single chamber TV-ICD devices did not and thus the total 
EGM signal length varies from 21 RR to 40 RR intervals prior to therapy delivery. See 
acceptable forms of sample data in Figure 4 below. Digitization was completed with 
MATLAB 2020a (The MathWorks, Inc.) via a custom written MATLAB script. 
Following digitization, all signals were visually adjudicated to ensure all EGM signals 
were transferred into ASCII with high fidelity. For a detailed description of the 






Figure 3: Picture of implanted S-ICD (left) and single chamber TV-ICD (right), box 
represents patient’s chest. Note that the TV-ICD has a single lead implanted 
directly into the heart via the venous system while the S-ICD system has a single 
lead implanted subcutaneously just to the left (from the patient’s perspective) of 
the sternum. 
 







42 of the 54 the digitized events were deemed appropriate based upon 
adjudication. 12 were labeled inappropriate. AF accounted for 11 of the inappropriate 
events, all occurring in single chamber TV devices, and there was 1 event of NSVT 
occurring with a S-ICD device. The dataset is made up of three device classes: Visia AF 
MRI VR / Evera XT VR (Medtronic) single chamber TV-ICDs, Dynagen EL ICD D150 
(BSci) single chamber TV-ICDs and Emblem MRI S-ICD A219 (BSci). The dataset is 
summarized in Table 2 below. 
Table 2: Summary of the dataset of digitized events. The parenthesis indicates the 








  VT VF NSVT AF 
Figure 4: Representative examples of acceptable far-field or “Shock” EGM signal for 
digitization. Top) signal adjudicated as VT, middle) signal adjudicated as VF and 
bottom) signal adjudicated as AF. Red arrows indicate important events such as the 
start of the signal with the number of RR intervals present, 16 RR intervals prior to 
the therapy and therapy delivery (not shown in the signal). These are cropped and 
modified pdf images taken from the case reports that are then stitched together. 
For a detailed description of the digitization process see Appendix A.1. 
 12 
Visia AF MRI VR / 
Evera XT VR 
(Medtronic) 
12 (1) 1 (0) 0 3 (1) 
Dynagen EL ICD D150 - 
VR (BSci) 
13 (1) 0 0 8 (2) 
Emblem MRI S-ICD 
A219 (BSci) 
4 (4) 12 (12) 1 (1) 0 
 
RR intervals as detected by the device were given on each case report. BSci single 
chamber TV-ICD case reports gave RR intervals to the exact ms and Medtronic single 
chamber TV-ICD case reports gave RR intervals rounded to 10 ms. S-ICD case reports 
did not give values for RR intervals, but still marked them on the document in a normal 
ECG grid (200 ms full thickness lines and 40 ms dotted lines). Thus, they could be 
estimated to the nearest 40 ms. After manually estimating the RR intervals for the 17 S-
ICD events, the RR intervals for each event were manually transferred into ASCII format 
from the case report.  
2.2 – Data Analysis Workflow 
 All data was analyzed via the workflow presented in Figure 5 on the next page. 
First, in step 1, pdf images of the EGM signals were digitized into ASCII as described in 
Appendix A.1. In step 2, the ASCII EGM signals and RR interval data for each event 
were segmented into the correct window size and 11 metrics, 4 novel nonlinear-based and 
7 RR-based were calculated. The 4 nonlinear-based metrics required the EGM signals 
and 7 RR-based required the RR interval data. Once all metrics were calculated for a 
dataset, step 3 was completed, in which the metrics were normalized via a Z-score using 
the mean and standard deviation of the dataset and input into a PCA or linear 




2.3 – Step 2.2: Nonlinear-based metrics 
4 novel Nonlinear-based metrics were utilized in this study: Multi-Scale Entropy (MSE), 
Shannon Entropy (SE), Multi-Scale Frequency (MSF) and Kurtosis. They were 
calculated using the windowed ASCII far-field/”Shock” EGM signals from each event. A 
detailed description of the techniques is available in Appendix A.2. MSE & SE should 
capture the randomness of the AF signals compared with the VT/VF signals, while AF 
should have a different MSF due to its erratic patterns. Moreover, Kurtosis should be 
different for the AF signals due to their different morphology when compared to VT/VF 
signals. Thus, these 4 novel techniques should be significantly different between the 
inappropriate (AF) and appropriate (VT/VF) events. 
2.4 – Step 2.3: Standard RR-based metrics 
7 RR-based metrics were utilized in this study: the mean RR interval (MeanRR), 
proportion of the successive differences in RR intervals (NNs) that exceeds 50 ms 
(pNN50), root mean square of the NNs (RMS), standard deviation of the NNs (STD), and 
Figure 5: Workflow for data analysis. Step 1) PDF image data was converted into 
ASCII and RR intervals manually entered. Step 2) The EGM signals and RR intervals  
were windowed (2.1) and then the Nonlinear-based metrics were calculated using 
the ASCII EGM signal (2.2) and Standard RR-based metrics calculated with the 
manually input RR intervals (2.3). Step 3) The metrics were then normalized with a 
Z-score and input into a PCA or therapy score system or analyzed with a boxplot. 
Manually input RR intervals Step 1 
Step 2 
Step 3 
Window EGM signal and RR intervals 
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the three Poincare metrics (SD1, SD2 and SD1/SD2). They were calculated using the 
manually input RR intervals from each event. A detailed description of the techniques is 
available in Appendix A.3. These techniques are similar to currently utilized stability 
measures and thus should show a difference between the inappropriate (AF) and 
appropriate signals (VT/VF) as AF typically has less stable RR intervals. 
2.5 – Step 3: Principal Component Analysis 
Principal component analysis (PCA) is commonly utilized to shrink the dimensionality of 
data. In this study, we have 11 metrics for each event. Making sense of the 11 metrics is 
challenging, but it is much easier to understand if we have 2 or 3 metrics to separate the 
data. Thus, PCA was utilized to reduce the dimensionality of the data to 2 or 3 
dimensions rather than 11. 
PCA transforms the large data set into a smaller one by creating linear combinations of 
the larger data set with the most possible variance. The most common approach when 
using PCA is to choose the number of principal components (PCs) to represent the data 
with based on the number of PCs that explain at least 95% of the variability in the data. 
However, given the desire to have the data be explained in only 2-3 metrics, the PCs are 
limited to 2-3 in this study, even though they may not contain 95% of the variability. 
Thus, the results of PCA on a given dataset are presented as the first 2-3 PC scores. PC 
coefficients greater than 0.3 are considered significant in this study [12]. 
2.6 – Step 3: Boxplots and Statistics 
Boxplots of the normalized data were created to analyze the different studies with 
MATLAB. All boxplots were analyzed with a one-way ANOVA with statistical 





Chapter 3 – Results  
3.1 – Research Question 1 – Does a long or short RR window prior to therapy lead 
to better retrospective discrimination? 
The first research question being asked was how many RR intervals one should consider 
prior to therapy when retrospectively evaluating therapy events. This question was being 
asked to determine if using a longer window led to more significantly different features 
than a shorter window just prior to therapy. Thus, the first study completed was a 
retrospective analysis looking at all RRs available prior to the therapy vs 16 RRs prior to 
therapy. When all RRs were used there was an uneven number of RR intervals between 
EGM signals, ranging from 40 RRs to 21 RRs in length. The EGM signals often began in 
sinus rhythm and transitioned into arrythmia at some point. In some events, the EGM 
signal was entirely arrythmia prior to therapy. With the 16 RR window, each signal was 
now a uniform 16 RRs in length. 16 RRs was chosen because upon visual inspection, this 
was the number of RRs for which every appropriate event EGM signal had progressed 
into VT/VF i.e., the entire signal is VT/VF for every appropriate event. 
Following windowing, box plots were created for the 11 metrics to compare the 
appropriate and inappropriate events. Only MSF and pNN50 were significantly different 
between the appropriate and inappropriate events for the all RRs window (Figure 6). 
Shrinking the window to be arrythmia only for the appropriate events (the 16 RR 
window), a majority of parameters became significantly different between the appropriate 
and inappropriate events, except for SD1/SD2 and MSE (Figure 7). 












Figure 6: Boxplots of the 
nonlinear-based (top) and 
RR-based (bottom) metrics 
across all RRs. * given for 
statistical significance 




    
 
 
    
Figure 7: Boxplots of the 
nonlinear-based (top) and 
RR-based (bottom) 
metrics for the 16 RRs 
prior to therapy delivery. 
* given for statistical 
significance between 

























    
The boxplot analysis was followed up by completing PCA on both datasets. The 
results of the PCA with the first two PC scores are given below in Figures 8 & 9. No 
clear visual discrimination can be made between the appropriate and inappropriate events 
when using the features of the all RRs dataset (Figure 8). However, the shorter 16 RR 






Figure 8: First two 















A 3-D plot of the first three PCs was also desired to see if better visual discrimination 
was possible by adding in the third PC. This was only done with the 16 RR window 
dataset. Similar levels of visual discrimination are possible on this plot, Figure 10 below, 
when compared to the 2-D plot of just the first two PCs above in Figure 9. 
 
 
Overall, the answer to this research question is that the 16 RR window is superior 
to the all RR window when retrospectively considering if therapy is appropriate or 
inappropriate. This is most likely because the NSR portions in some of the appropriate 
events of the all RR windows was tricking the metrics and PCA into thinking the rhythm 
was more NSR like than VT/VF like. Thus, in order for the metrics plus PCA to 
accurately separate appropriate therapy from inappropriate therapy, the window size must 
be chosen such that all of the appropriate events are in VT/VF for the entire duration of 
the window. In this study, this is the 16 RR window. 
Figure 9: First two PC 
scores for the 16 RR 
window prior to therapy 
delivery. A solid black 
line was placed to aid in 
visual discrimination. 
Figure 10: First three PC 
scores for the 16 RR 




3.2 – Research Question 2 – Does arrythmia type and/or manufacturer influence 
discrimination? 
Following the success of the 16 RR window dataset with PCA to discriminate between 
the appropriate and inappropriate events, it was desired to see if the different arrythmias 
(VT, VF, AF, NSVT) could be separated from each other as well. As such, the events 
were sorted by arrythmia type – VT, VF and AF – for the below boxplot analysis in 
Figure 11. AF accounted for 11 of the 12 inappropriate events while VT/VF accounted 
for all 42 of the appropriate events. The singular NSVT event was removed because there 
was only one of them. We see that between VT or VF and AF the same parameters 
remain statistically significant as in Figure 7 above. 
     
     
 
Figure 11: Boxplots of the 
nonlinear-based (top) and RR-
based (bottom) metrics for the 
16 RRs prior to therapy 
delivery, separated by 
arrythmia type. * given for 
statistical significance between 

























Next, PCA was completed on the 16 RR dataset once again. The PCA is identical 
to the one shown with the 16 RR dataset (Figure 9) except for how the resulting 2-D (first 
two PCs) and 3-D (first three PCs) plots are labeled. In these plots, Figures 12 and 13 
below, the events are labeled by their arrythmia type VT or VF for appropriate events and 
AF or NSVT for the inappropriate events. The inappropriate events are also labeled by 
manufacturer, BSci or Medtronic. With this analysis, it was seen that the VT and VF 
groups were not clearly visually distinguishable from one another but remained 
distinguishable from the inappropriate therapy rhythm groups. While VT and VF signals 
typically have different morphology, they do tend to have similar regularity to their RR 
intervals. As such, the aforementioned result was not surprising. Figures 12 & 13 also 
show that most of the inappropriate BSci events are further separated from the 






Figure 12: First two PC scores for 
the 16 RR window prior to therapy 
delivery but separated by 
arrythmia type and manufacturer. 
Inappropriate BSci cases 
surrounded by purple ovals while 
inappropriate Medtronic cases are 
surrounded by orange ovals. A 






Digging further into the PCA analysis of the 16 RR window, the loading 
coefficients for the first three PCs were analyzed to see which parameters were 
contributing a significant portion to the formation of the PC score. These are given below 
in Table 3. Across the first three PCs every parameter contributed in a significant way to 
at least one PC. The first PC was primarily composed of the RR-based metrics while the 
second PC was more heavily biased by the nonlinear-based metrics. PC3 was heavily 
influenced by MSF, MSE and SD1/SD2.  
Table 3: Loading coefficients for the PCA of Study 2 and Study 3. Significant 
contributions are bolded. 
  Loading Coefficients 
  PC1 PC2 PC3 
MSF 0.272 -0.148 0.438 
MSE 0.068 0.402 0.705 
SE -0.285 0.336 0.064 
Kurt 0.303 -0.400 0.042 
MeanRR 0.244 -0.416 -0.162 
pNN50 0.375 0.118 -0.006 
RMS 0.367 0.219 -0.122 
STD 0.376 0.174 -0.050 
SD1 0.367 0.220 -0.124 
Figure 13: First three PC 
scores for the 16 RR window 
prior to therapy delivery but 
separated by arrythmia type 
and manufacturer. 
Inappropriate BSci cases 
surrounded by purple ovals 
while Inappropriate 
Medtronic cases are 
surrounded by orange ovals.  
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SD2 0.370 0.131 0.011 
SD1/2 0.027 0.461 -0.497 
 
Lastly, it was desired to see how many PCs actually encompassed 95% of the 
variability with the PCA of the 16 RR window. Thus, Figure 14 below was created which 
shows the percent variance explained by each PC up to 95% of the total. First, it was seen 
that it requires 5 PCs to cover 95% of the total variance in the data. However, the first 
two PCs represent roughly 80% of the variance, and the first three represent almost 90% 
of the variance. Thus, while not meeting the typical requirement of 95% of variability 
covered in the utilized PCs, the first two and three PCs do cover a majority of the 
variability in the data.  
 
 
Overall, answering this research questions showed that the inappropriate BSci 
events were typically further separated from the appropriate events compared to the 
inappropriate Medtronic events. This may be a result of the programming of the devices. 
All 3 Medtronic events had stability analysis turned on at either 40 or 50 ms, while most 
of the BSci events had it turned off. Stability analysis (described in the introduction) is 
similar to the RR-based metrics used in this study. As such, if turned on, it should have 
prevented inappropriate therapy for highly variable RRs. PC1 is primarily composed of 
the RR-based metrics, and thus a PC1 greater than a certain value is computing a similar 
decision to stability analysis. Thus, most likely, most of the events of inappropriate 
Figure 14: Bar plot showing 
the percent variance 
explained by each PC up to 
95% of the total variance. 
The cumulative total variance 
explained as the amount is 
summed from PC 1 to 5 is 
given by the solid line.  
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therapy on BSci devices would have been prevented by programming the stability 
analysis on.  
This finding begs an important question: what is the advantage of these metrics 
plus PCA when compared with existing algorithms to retrospectively separate the 
signals? The advantage is that the combination of the seven RR-based metrics should 
provide better sensitivity than a single metric as used in the stability analysis. This is seen 
in that 2 out of the 3 Medtronic events lie to the right of the black line in Figure 12, even 
though they had stability analysis turned on. 
 
3.3 – Research Question 3 – Does separating the data by manufacturer into two 
separate datasets improve discrimination? 
Given the findings of research question 2 that the inappropriate Medtronic events 
were less separated from the appropriate events compared to most of the BSci events, the 
two manufacturers’ devices were individually investigated. It was hoped that separating 
them would lead to better visual separation between the appropriate and inappropriate 
events. To this end, the 16 RR dataset was separated into a Medtronic dataset and BSci 
dataset after all metrics were calculated and before normalization. Normalization with a 
Z-score was then completed and PCA completed on each dataset. Figures 15 and 16 
below show the results of the PCA. In both figures, all inappropriate events (AF) are 
clearly separated from the appropriate events (VT/VF) based on visual discrimination. 
 
Figure 15: First three PC 
scores for the 16 RR window 
prior to therapy delivery, but 
only for Medtronic single 




  To investigate why there was better separation when doing PCA on the two 
separated data sets, the loading coefficients for the first three PCs were compiled in 
Tables 4 & 5 below. The loading coefficients in Table 4 for the BSci devices remained 
similar to those for the entire dataset in Table 3. However, the loading coefficients for the 
separated Medtronic dataset in Table 5 had significant change. The MeanRR, STD and 
SD2 did not significantly contribute to any of the first three PCs, MSE contributed much 
more to PC1 and not the second two, MSF contributed much more to PC2 rather than 
PC3, SE contributed more to PC2 and PC3 and less to PC1 and lastly Kurtosis switched 
its significant contributions from PC1 and PC2 to PC3. 
Table 4: Loading coefficients for the PCA of the BSci dataset.  
  
  Loading Coefficients 
  PC1 PC2 PC3 
MSF 0.268 -0.182 0.395 
MSE 0.043 0.344 0.731 
SE -0.305 0.334 0.158 
Kurt 0.315 -0.377 0.006 
MeanRR 0.281 -0.367 -0.147 
pNN50 0.377 0.106 0.000 
RMS 0.354 0.261 -0.089 
STD 0.365 0.211 -0.013 
SD1 0.354 0.262 -0.091 
Figure 16: First three PC 
scores for the 16 RR window 
prior to therapy delivery, but 
only for BSci single chamber 
TV devices and BSci S-ICD 
devices.  
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SD2 0.359 0.160 0.050 
SD1/2 -0.002 0.492 -0.494 
 
Table 5: Loading coefficients for the PCA of the Medtronic dataset.  
  
  Loading Coefficients 
  PC1 PC2 PC3 
MSF 0.153 -0.374 0.123 
MSE 0.497 -0.174 -0.022 
SE -0.061 0.616 -0.481 
Kurt -0.047 -0.124 0.552 
MeanRR -0.179 0.269 0.219 
pNN50 0.437 0.283 0.209 
RMS 0.316 0.197 0.136 
STD 0.287 0.204 0.122 
SD1 0.317 0.197 0.137 
SD2 0.255 0.205 0.105 
SD1/2 0.390 -0.348 -0.541 
 
Overall, splitting up the data into two datasets, one for each manufacturer, led to 
good visual separation with both datasets. This is because the PCA relied upon a unique 
combination of measures for creating the first few PCs for the Medtronic dataset. In 
doing so, it visually separated all 3 inappropriate Medtronic events from the appropriate 
Medtronic events even though they had regular RRs and thus stability analysis failed to 
withhold therapy. Despite these promising results, separating the datasets is not ideal as 
this would mean for all future investigations the datasets would need to be split based 
upon manufacturer. 
3.4 – Research Question 4 – Do the therapy scores discriminate appropriate and 
inappropriate therapy? 
The last retrospective study completed was to look at using a linear combination score 
termed “therapy scores” to discriminate between the appropriate and inappropriate 
events. The therapy scores were separated into a nonlinear therapy score (NonLinScore) 
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and RR therapy score (RRScore). The NonLinScore was formed as NonLinScore = MSF 
– SE + Kt. The RRScore was formed as RRScore = MeanRR + pNN50 + RMS + STD + 
SD1 + SD2. Both scores were formed by simply summing the statistically significant 
parameters from the boxplot analysis in study 2 (Figure 9). The only exception to 
summing was a subtraction of SE because SE was significantly decreased in the 
Inappropriate events when compared with the Appropriate events in Figure 9. The 
insignificant metrics MSE and SD1/SD2 were left out the therapy scores.  
The innovative idea for the therapy scores came about because when looking at the 
previous PCA analysis in research questions 1-3 it was seen that parameters such as 
SD1/SD2 and MSE were making significant contributions to the PCs even though they 
were not statistically different between the inappropriate and appropriate groups. This is 
because PCA shrinks the dimensionality by looking at how much variability across the 
entire dataset can be explained by each metric. So even though they weren’t statistically 
different, there was still a large amount of variability in the entire dataset with these 
metrics and thus they were significantly utilized in the creation of the first few PCs. The 
therapy scores also make it clear to see the difference in the RR-based metrics and the 
Nonlinear-based metrics between the appropriate and inappropriate events. 
Figure 17 below shows the results of using the RRScore and NonLinScore to separate the 
16RR dataset rather than PCA. Similar visual discrimination was achieved with this 
method compared to PCA. However, rather than representing the discrimination with a 
line, a black box of RRScore and NonLinScore < 2.5 is utilized. This region is thusly 
termed the “Appropriate Therapy Zone” or ATZ. All appropriate events are within the 
ATZ while only 1 inappropriate event is inside it. Moreover, the utility of the ATZ can be 
seen in that 3 Inn events were only visually distinguishable based upon their RRScore 
(RRScore > 2.5 & NonLinScore < 2.5) while 1 inappropriate event was only 
distinguishable upon its NonLinScore (RRScore < 2.5 & NonLinScore > 2.5). Thus, if 
only the RRScore or only the NonLinScore was used to determine if the therapy was 




3.5 – Research Question 5 – Do the retrospective strategies work for real time 
decision making? 
Research questions 1-4 were all retrospective studies looking at a window of RRs from 
the known therapy backwards. Thus, with research question 5, it was desired to 
investigate if PCA or the therapy scores and ATZ could visually distinguish whether or 
not to provide therapy across time. In this sense, once a datapoint moved into a specified 
area the device would deliver therapy.  
5 events (2 Appropriate and 3 Inappropriate) directly following a previous therapy 
were removed from the dataset as the focus of this study was the decision to deliver the 
first therapy. Next, 25 RR interval window lengths of each EGM signal were then 
obtained. Each 25 RR interval window was then split into 4 successive windows of 10 
RR, each with 5 RR overlap. See Figure 18 below to visualize the sliding windows. Each 
10 RR window was then normalized with the Z-score using the mean and standard 
deviation across all of the 10 RR windows. Boxplots for the first and fourth windows 
were then generated to compare the measures across time Figures 19 and 20. This 
“pseudo” real time analysis is thusly looking at a short window a few seconds prior to the 
delivery of the first therapy and then at another short window right before the first 
therapy is delivered. With window 1 the only statistically significant parameter was MSF, 
while with window 4, all parameters except for MSE, MeanRR and SD1/SD2 were 
Figure 17: RRScore on 
the x-axis and 
NonLinScore on the y-




The ATZ is the area 
inside the black box. 
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statistically significant. This illustrates a change in the properties of many of the 
appropriate EGM signals from window 1 to window 4. This is expected because many of 











Figure 18 : 4 windows of 10 RR length created from 25 RR prior to therapy.  
Figure 19: Boxplots of the Nonlinear-based metrics for the first (left) and fourth 
























    
 
    
 
PCA was then completed with all of the 10 RR windows to generate the 1st and 
2nd PC for each window (Figure 21). With window 1, we see no clear visual separation 
between the inappropriate and appropriate events. However, as we move from window 1 
and window 2 to window 3, we see movement of all of the appropriate events to a PC1 of 
less than 0, while most inappropriate events maintain a PC1 greater than 0. The hope was 
then that all of the appropriate events would move into the specified area (PC1 < 0) by 
window 4 and none of the inappropriate events to do so. However, 2 inappropriate events 
moved into the specified area by window 4. Moreover, it is important to note that a 
Figure 20: Boxplots 
of the RR-based 
metrics for the first 





























majority of the appropriate events began in the specified area in Window 1. This is 
because a majority of the events began in VF/VT. There is then limited movement of 




Beyond PCA, the use of the therapy scores was also investigated for its ability to separate 
the signals in a “pseudo” real time fashion. As such, instead of completing PCA, the 
previously described RRScore and NonLinScore were applied to the datasets of windows 
1-4. The results of this investigation are given below in Figure 22. Based on the visual 
separation in Figure 22, the ATZ was determined as the region of a RRScore less than 0 
and NonLinScore less than 2.5. In windows 1 and 2, a slight majority of the number of 
appropriate events are within the ATZ while none of the inappropriate events. By 
Figure 21: The first two PC scores for each 10 RR window dataset: Window 1 (top 
left), Window 2 (top right), Window 3 (bottom right) and Window 4 (bottom left). 
Black line added to aid with visual discrimination. 
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window 3 all but 1 appropriate event has entered the ATZ, which subsequently enters the 
ATZ in window 4. Meanwhile, none of the inappropriate events ever enter the ATZ. This 
is more ideal when compared with the PCA. 
 
 
  Figure 22: Plots of the RRScore vs. NonLinScore for each 10 RR window dataset: 
Window 1 (top left), Window 2 (top right), Window 3 (bottom right) and Window 
4 (bottom left). The ATZ is given by the black box. 
Black line added to bottom figures to aid with visual discrimination. 
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Chapter 4 – Summary 
4.1 – Major Conclusions 
The primary goal of this thesis was to develop novel strategies for discrimination 
between inappropriate and appropriate ICD therapy. The novelty of the new strategies is 
that they utilize a combination of 4 novel nonlinear metrics in addition to 7 standard RR-
based metrics fed into PCA or linear combination scores (therapy scores) to discriminate 
rather than traditional rate, morphology, stability and onset analysis to determine if a 
rhythm is appropriate for therapy. In evaluating the novel strategies, the thesis addressed 
5 primary research questions: 
1) Does a long or short RR window prior to therapy lead to better retrospective 
discrimination? 
a. Short 16 RR windows were far superior to longer windows of variable 
RR length ranging from 21-40 RRs when completing retrospective 
discrimination. 
2) Does arrythmia type and/or manufacturer influence discrimination? 
a. There was no distinction between discrimination of VT or VF from 
AF. Inappropriate BSci cases were further from the appropriate 
therapy group than inappropriate Medtronic cases. 
3) Does separating the data by manufacturer into two separate datasets improve 
discrimination? 
a. Separating the data by manufacturer improved discrimination, but 
ideally all cases should be discriminable independent of manufacturer. 
4) Do the therapy scores discriminate appropriate and inappropriate therapy? 
a. Linear combination scores performed similarly to the PCA strategy 
used in answering research questions 1-3. 
5) Do the retrospective strategies work for real time decision making? 
a. Both PCA and therapy scores show promise for use in real time 
therapy decision making, but the therapy scores outperformed PCA. 
From these answers, three major conclusions were made: 
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1. Both PCA and the therapy scores show promise in discriminating between 
appropriate and inappropriate therapies retrospectively across Medtronic and 
BSci single chamber TV and S-ICD devices. 
2. When completing retrospective analysis, short windows just prior to therapy 
provide clear visual separation between the inappropriate and appropriate 
therapy groups, while long windows do not. 
3. Real time therapy decision making is feasible with both PCA and the therapy 
scores, but the therapy scores in conjunction with the ATZ show more 
promise. 
4.2 – Limitations 
The major limiting factor of this entire experiment was the small and unbalanced dataset. 
Recent clinical studies have nearly 10x the number of appropriate therapies and 10x to 
100x the number of inappropriate therapies in their datasets [4, 7]. To draw conclusions 
of similar significance, the dataset would need to be at least the same size, if not a larger 
size. Moreover, more inappropriate events from S-ICD devices are needed, especially 
since most of the inappropriate therapy in S-ICD devices is caused by oversensing, not 
SVTs. 
A limitation of the “pseudo” real time analysis was that many of the events were already 
in arrythmia at the start of the analysis in Window 1. Ideally, the signals would all have 
started in NSR or other baseline rhythm and then transitioned into VT/VF. Otherwise, it 
is unknown if some of the patient’s baseline rhythms would fall within the ATZ and 
cause the delivery of an inappropriate therapy. Lastly, this experiment only looked at 
Medtronic and BSci devices. Including other manufacturers such as Biotronik would 
make the experiment more robust. 
4.3 – Future Directions 
An algorithm utilizing the therapy score and ATZ should be investigated first in a larger 
retrospective study with a dataset tenfold larger. Machine learning could also be used in 
this study to optimize the ATZ. The next step would be to program this into actual 
devices and then complete a clinical study in conjunction with the manufacturers. The 
algorithm could also be used retrospectively to adjudicate events and relieve 
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Cardiologists of this duty. However, it must first be validated on a larger dataset to ensure 
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A.1 – Digitization  
1. Screenshot the desired EGM signal. 
2. In the MacOS preview, adjust the threshold of the cropped image to remove 
dotted lines and other noise from the image so only the EGM signal is left. 
MATLAB can also be used for this. 
3. Save as a 300 dpi image with size adjustment making sure to not resample the 
image. 
4. Upload the image to MATLAB. 
5. Using a custom written MATLAB script, set all pixels in the image with a 
grayscale value less than 200 to 0. The only remaining pixels with a value 
other than 0 should be the pixelated trace of the EGM signal. 
6. Plot the pixelated trace and fit a smoothing spline to the pixelated trace.  
7. Using a discrete index set by your desired sampling frequency and length of 
the EGM trace in time (taken from the case reports), sample the smoothing 
spline fit to get the digitized signal. 
8. Plot the final digitized signal and the pixelated trace to ensure high fidelity 
digitization. 
9. Save the digitized signal in ASCII format for analysis with MATLAB. 
A.2 – Detailed description of Nonlinear-based Metrics 
MSE & SE 
Entropy measures such as multi-scale entropy (MSE) are typically utilized to 
quantify the complexity of a signal through quantification of a signals “uncertainty.” 
Commonly used entropy measures for biomedical signals includes Shannon Entropy 
(SE), Sample Entropy, etc. In fact, SE has shown decent prognosis in identifying AF on 
ECG data [13]. Thus, SE may work well to identify AF when compared with VF/VT. 
However, standard entropy based measures such as SE may fail when the data becomes 
non-stationary such as with EGM recordings. MSE was designed to overcome this 
limitation by incorporating information from the “past” and “future” in the form of a 
moving average kernel. Because the heart rhythm becomes more complex during VF/VT 
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compared with non-VF/VT rhythms, it was hypothesized that the improved MSE will 
significantly increase once the heart enters VF/VT. 
The improved MSE utilizes a nearest-neighbor moving-average kernel. This 
measure has previously been used to accurately discriminate atrial fibrillation [14]. A full 
description of the technique can be found in Ref. [14]. For this MSE, a scale factor  must 
be chosen for the nearest-neighbor moving-average kernel as  controls the number of 
samples averaged over. A scale factor of  = 10 was chosen for this research as it has 
been shown that the optimal  for rotor pivot point identification is 10 in unpublished 
work by the Talkachova lab. Values of the delay factor, 𝛿, and length of matching 
segments, 𝑚, was left as 1 and 2 as was previously suggested for atrial fibrillation 
discrimination [14]. 
MSF 
In this study, an improved multiscale frequency measure is utilized. It has 
previously been reported to accurately identify the pivot point of rotors [15] [16]. A full 
description of the technique can be found in Ref. [16]. The improved MSF combines 
local estimates of instantaneous frequency over many time scales. This helps account for 
the nonstationary nature of the heart which makes common frequency based approaches 
less useful for analysis of EGMs. The center frequency for the 8 log-Gabor filters used in 
this method were chosen to span a physiological range for the human heart. Thus, it is 
hypothesized that as the patient enters VF/VT their EGM will change in frequency 
characteristics and the MSF value will be different then in the case of non VF/VT such as 
AF, NSR or oversensing.  
Kurtosis 
Sample Kurtosis (simplified to kurtosis in this study) is the third feature measured 
in this study. Kurtosis is a higher order statistical measure known as the fourth 
standardized moment of the sample distribution. It measures the combined weight of the 
tails of the sample distribution in comparison to the weight of the center of the sample 
distribution. The kurtosis of a normal distribution is 3. Distributions with larger tail to 
center ratios than a normal distribution have kurtosis greater than 3 and those with 
smaller ratios have kurtosis less than 3. The definition of kurtosis utilized in this study is 
given by MATLAB in Ref. [17] where kurtosis is assumed as biased with a flag of 1. 
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Kurtosis should note changes in the morphology of signals. Thus, it was expected 
that the distinct morphological changes in a VF/VT signal compared to a non-VF/VT 
signal would cause kurtosis to be significantly different between VF/VT and non-VF/VT 
rhythm. 
A.3 – Description of RR-based metrics 
1. MeanRR 
a. The MeanRR is simply the mean value of all of the RR values. 
2. pNN50 
a. pNN50 stands for the percentage of NNs (differences between successive 
RR intervals) greater than 50 ms. The larger pNN50 is, the more 
variability in the RR intervals. 
3. RMS 
a. The root mean squared value of the NNs. 
4. STD 
a. The standard deviation of the NNs. 
5. SD1 
a. The variance between the sum of the current RR intervals and the next RR 
intervals divided by the square root of 2. Typically associated with short-
term RR interval variability. 
6. SD2 
a. The variance between the difference of the current RR intervals and the 
next RR intervals divided by the square root of 2. Typically associated 
with long-term RR interval variability. 
7. SD1/SD2 
a. The ratio between SD1 and SD2. 
